JP2011521947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521947A5 JP2011521947A5 JP2011511647A JP2011511647A JP2011521947A5 JP 2011521947 A5 JP2011521947 A5 JP 2011521947A5 JP 2011511647 A JP2011511647 A JP 2011511647A JP 2011511647 A JP2011511647 A JP 2011511647A JP 2011521947 A5 JP2011521947 A5 JP 2011521947A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- substituted
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 55
- 150000001875 compounds Chemical class 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 125000000539 amino acid group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000002950 monocyclic group Chemical group 0.000 claims 14
- 108010069514 Cyclic Peptides Proteins 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 239000000816 peptidomimetic Substances 0.000 claims 12
- -1 polycyclic hydrocarbon Chemical class 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000002738 chelating agent Substances 0.000 claims 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 7
- 239000004215 Carbon black (E152) Substances 0.000 claims 7
- 229920002674 hyaluronan Polymers 0.000 claims 7
- 229960003160 hyaluronic acid Drugs 0.000 claims 7
- 229930195733 hydrocarbon Natural products 0.000 claims 7
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 7
- 102000001189 Cyclic Peptides Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 108700012439 CA9 Proteins 0.000 claims 5
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229960000397 bevacizumab Drugs 0.000 claims 5
- 229960004397 cyclophosphamide Drugs 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 229960004679 doxorubicin Drugs 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229960001592 paclitaxel Drugs 0.000 claims 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 5
- 229960004618 prednisone Drugs 0.000 claims 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 5
- 229960001052 streptozocin Drugs 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 125000001425 triazolyl group Chemical group 0.000 claims 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 5
- 229960004528 vincristine Drugs 0.000 claims 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 5
- 230000003197 catalytic effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 230000005251 gamma ray Effects 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 0 C**(C)(C)CCSC(CC(N1CCC(NC(CCCCNC(C[n]2nnc(CCC*)c2)=O)C(NCCCCC(*([C@@]2Cc3ccccc3)(C2=O)C([C@](CC(O)=O)N*(CNC(C(CCCNC(N)=N)N2)=O)=O)=O)C2=O)=O)=*)=O)C1=* Chemical compound C**(C)(C)CCSC(CC(N1CCC(NC(CCCCNC(C[n]2nnc(CCC*)c2)=O)C(NCCCCC(*([C@@]2Cc3ccccc3)(C2=O)C([C@](CC(O)=O)N*(CNC(C(CCCNC(N)=N)N2)=O)=O)=O)C2=O)=O)=*)=O)C1=* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5777408P | 2008-05-30 | 2008-05-30 | |
| US61/057,774 | 2008-05-30 | ||
| PCT/US2009/003309 WO2009148554A1 (en) | 2008-05-30 | 2009-06-01 | Achievement of high therapeutic index through molecular imaging guided targeted drug treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521947A JP2011521947A (ja) | 2011-07-28 |
| JP2011521947A5 true JP2011521947A5 (https=) | 2011-10-13 |
| JP5681102B2 JP5681102B2 (ja) | 2015-03-04 |
Family
ID=40904366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511647A Expired - Fee Related JP5681102B2 (ja) | 2008-05-30 | 2009-06-01 | 分子イメージング手法のための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8293206B2 (https=) |
| EP (1) | EP2288388B1 (https=) |
| JP (1) | JP5681102B2 (https=) |
| KR (1) | KR20110020874A (https=) |
| CA (1) | CA2726050A1 (https=) |
| WO (1) | WO2009148554A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| HRP20220455T1 (hr) | 2012-08-31 | 2022-05-27 | Sutro Biopharma, Inc. | Modificirane aminokiseline koje sadrže azid grupu |
| KR20170042495A (ko) | 2013-12-16 | 2017-04-19 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| CA2994853C (en) | 2015-08-14 | 2023-06-27 | Rc Biotechnologies, Inc. | Covalent linkers in antibody-drug conjugates and methods of making and using the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769271A (en) * | 1971-04-15 | 1973-10-30 | Lilly Co Eli | N-protected amino acids and peptides |
| US5188816A (en) | 1984-10-18 | 1993-02-23 | Board Of Regents, The University Of Texas System | Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS |
| EP0247156B1 (en) | 1985-11-18 | 1993-06-23 | Access Pharmaceuticals Inc. | Polychelating agents for image and spectral enhancement (and spectral shift) |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5219553A (en) | 1986-08-04 | 1993-06-15 | Salutar, Inc. | Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI |
| US5087440A (en) | 1989-07-31 | 1992-02-11 | Salutar, Inc. | Heterocyclic derivatives of DTPA used for magnetic resonance imaging |
| US5262532A (en) | 1991-07-22 | 1993-11-16 | E.R. Squibb & Sons, Inc. | Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| DE19728524A1 (de) | 1997-07-04 | 1999-01-07 | Merck Patent Gmbh | Cyclische Azapeptide |
| US6537520B1 (en) * | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US20030125243A1 (en) * | 2000-07-20 | 2003-07-03 | Jun Liu | Synthesis of cyclic peptides |
| US20090104119A1 (en) * | 2004-08-25 | 2009-04-23 | Majoros Istvan J | Dendrimer Based Compositions And Methods Of Using The Same |
| AU2005294214A1 (en) * | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
| EP1733742A1 (en) * | 2005-06-17 | 2006-12-20 | Universiteit Utrecht Holding B.V. | Dendrimers multivalently substituted with active groups |
| CA2617907A1 (en) * | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| WO2008033557A2 (en) | 2006-09-15 | 2008-03-20 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclic peptidomimetics as integrin markers |
| EP2061519B1 (en) * | 2006-09-15 | 2016-03-30 | Siemens Medical Solutions USA, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
| US8043601B2 (en) * | 2007-07-27 | 2011-10-25 | Siemens Medical Solutions Usa, Inc. | Cyclic azapeptides as integrin markers |
-
2009
- 2009-06-01 EP EP09758718.2A patent/EP2288388B1/en not_active Not-in-force
- 2009-06-01 JP JP2011511647A patent/JP5681102B2/ja not_active Expired - Fee Related
- 2009-06-01 CA CA2726050A patent/CA2726050A1/en not_active Abandoned
- 2009-06-01 US US12/455,346 patent/US8293206B2/en active Active
- 2009-06-01 KR KR1020107029748A patent/KR20110020874A/ko not_active Ceased
- 2009-06-01 WO PCT/US2009/003309 patent/WO2009148554A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102902487B1 (ko) | 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도 | |
| JP7162592B2 (ja) | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 | |
| US11497819B2 (en) | PSMA ligands for imaging and endoradiotherapy | |
| JP2022023172A (ja) | 陽電子放出断層撮影用の化合物 | |
| JP2010523599A5 (https=) | ||
| RU2011127468A (ru) | Технецкий- и рений-бис(гетероарильные) комплексы и методы их применения для ингибирования psma | |
| JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| JP2011521947A5 (https=) | ||
| JP7646637B2 (ja) | 画像化及び治療用組成物 | |
| CN116217505B (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| US20250375544A1 (en) | Dual mode radiotracer and -therapeutics | |
| KR20140053819A (ko) | 방사선요법용 177루테튬-표지 봄베신 유사체 | |
| US20240293586A1 (en) | Radiolabeled compound and use thereof | |
| CN116472068A (zh) | 治疗性放射性标记的缀合物及其在疗法中的用途 | |
| JP7824281B2 (ja) | ガストリン放出ペプチド受容体アンタゴニストを含むコンジュゲートまたはその塩およびそれらの使用 | |
| US20230406847A1 (en) | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks | |
| CN104321083B (zh) | 用于成像和治疗的亚乙双半胱氨酸‑糖缀合物的有效合成 | |
| US8454936B2 (en) | Metal chelators and methods of their use | |
| US20260053960A1 (en) | Dimeric radiopharmaceuticals, compositions thereof and uses thereof | |
| US12486294B2 (en) | Radioisotope labeled compound for imaging or treatment of prostate cancer | |
| CN118302202A (zh) | 用于治疗癌症的化合物及其组合物 | |
| JP5971867B2 (ja) | ガリウム標識薬剤 | |
| HK1192487A (en) | 177 lutetium-labeled bombesin analogs for radiotherapy |